CLINICAL_TRIALS ClinicalTrials.gov record update

Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07203846
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:13.480197+00:00
Published At: 2025-10-02T00:00:00+00:00
Record Updated At: 2025-10-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["ACS - Acute Coronary Syndrome", "Ticagrelor", "Microbiota", "Platelet Aggregation", "Myocardial Infarction (MI)", "Blood Platelets", "Drug Effects", "Platelet Aggregation Inhibitors", "Drug Resistance", "Platelet Function Tests", "Dysbiosis", "Anti-Bacterial Agents", "Rifaximin"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-02"
protocolSection.identificationModule.nctId: "NCT07203846"
protocolSection.identificationModule.officialTitle: "Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.